Lynnette Jackson is a native of Indiana, graduating with a degree from Indiana University in Biology Education. Her first professional employment was with Biomet, where she managed a production laboratory. She advanced to a position at Biomet in the Quality and Regulatory Affairs department and began to learn the regulations and requirements of the United States Food and Drug Administration as well as those of countries around the world. Mrs. Jackson took on roles of increasing responsibility at other orthopedic companies including five years at both Zimmer and DePuy, and with SpineVision, a start-up spinal company based in Paris, France. Her significant and varied experience over a span of nearly 30 years includes the areas of quality assurance/quality control, labeling, regulatory compliance, regulatory submissions, and both pre- and post-market clinical studies. She has managed these areas at a senior level for successful start-up companies, and for large, orthopedic industry-leading companies.
Mrs. Jackson joined Biomet as Vice President of Quality/Clinical/Regulatory Affairs, leading the company through many successful FDA and foreign government inspections, restructuring and improving multiple departments, and launching several major clinical studies. She later advanced to the position of Vice President, Global Regulatory Affairs for Biomet Orthopedics. In this role, she managed all activities related to worldwide regulatory submissions in pursuit of approval for marketing of products. She also managed the global labeling activities for all products, launched a major software system, and managed the successful integration of DePuy’s trauma line into the Biomet product portfolio. Mrs. Jackson has established contacts within the FDA and foreign regulatory bodies, influenced the content of regulations and guidance documents, and served on the Board of Directors and governing structure of the Orthopedic Surgical Manufacturer’s Association. She has significant experience with multiple orthopedic products including anti-infectives and biologics, and across a range of regulatory requirements, both domestically and internationally.